| Active substance | teclistamab |
| Holder | Janssen-Cilag NV |
| Status | Closed |
| Indication | monotherapy, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior lines of therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and who have exhausted all commercially approved and clinically appropriate treatment options, are ineligible for a clinical trial and have evidence of disease progression after the last therapy |
| Public documents | Approbation |
| Approbation amendement | |
| Information for the patient | |
| Informed consent | |
| Last update | 05/09/2023 |